Gabryelewicz A, Kosidło S, Marlicz K, Jaroszewicz-Heigelmann H
Klinik Gastroenterologii Akademii Medycznych, Białymstoku.
Wiad Lek. 1993 Mar;46(5-6):183-5.
The purpose of the work was an evaluation of duodenal ulcer recurrence rate in patients with a history of at least two years of ulcer treated during one year with the preparation Ulfamid (famotidine) Krka in a maintenance dose of 20 mg before sleep. The study involved 30 patients of either sex in whom complete healing of the ulcer niche was obtained in the first phase. Control endoscopy was carried out after 3, 6, 9, and 12 months. In the first phase of the study, complete healing of the ulcer niche after the treatment with Ulfamid in a therapeutic dose of 40 mg for six weeks was obtained in 94.9%. In the second phase of the study, after three months on Ulfamid in a maintenance dose, the recurrence rate was 13.3%, after six months 26.6%, after nine months another 6.1%. After 12 months the recurrence rate of duodenal ulcer reached jointly 46.7%. Of interest is the observation of a large number of the so called asymptomatic ulcers which accounted for 50% of the observed recurrencies.
这项工作的目的是评估曾用乌尔法米德(法莫替丁)克尔卡制剂以20毫克睡前维持剂量治疗溃疡至少两年的患者,在接受一年治疗后十二指肠溃疡的复发率。该研究纳入了30名男女患者,他们在第一阶段实现了溃疡龛的完全愈合。在3、6、9和12个月后进行了对照内镜检查。在研究的第一阶段,94.9%的患者在以40毫克治疗剂量服用乌尔法米德六周后实现了溃疡龛的完全愈合。在研究的第二阶段,服用维持剂量的乌尔法米德三个月后,复发率为13.3%,六个月后为26.6%,九个月后又为6.1%。12个月后,十二指肠溃疡的总复发率达到46.7%。值得关注的是观察到大量所谓的无症状溃疡,其占观察到的复发病例的50%。